Gwénaël Ferron
YOU?
Author Swipe
View article: Proposed strategy after complete LAMN (low-grade appendiceal mucinous neoplasm) resection by different RENAPE units: need for a new consensus?
Proposed strategy after complete LAMN (low-grade appendiceal mucinous neoplasm) resection by different RENAPE units: need for a new consensus? Open
Objectives To evaluate current postoperative management strategies for incidentally discovered, completely resected low-grade appendiceal mucinous neoplasms (LAMNs) within the French RENAPE network and to assess the need for a new national…
View article: Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer
Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer Open
PURPOSE In patients with ovarian cancer undergoing neoadjuvant chemotherapy (NACT) with the goal of achieving complete interval cytoreductive surgery (ICS), tools are needed to accurately assess NACT efficacy and predict the feasibility of…
Adjuvant treatment algorithm based on recent ESGO/ESTRO/ESP guidelines for early endometrial carcinoma according to prognostic risk groups Open
The incidence of endometrial cancer (EC) is unfortunately increasing. Often diagnosis is made at an early stage and surgery is the curative treatment. Nevertheless, adjuvant treatment is proposed to reduce the risk of relapse. This treatme…
View article: Tetraploidization-driven PRKG1 deletion reveals novel mechanisms underlying Leiomyosarcoma aggressiveness
Tetraploidization-driven PRKG1 deletion reveals novel mechanisms underlying Leiomyosarcoma aggressiveness Open
Leiomyosarcoma (LMS) is a malignant mesenchymal tumor with smooth muscle cell (SMC) differentiation. LMS shows high metastatic rate and highly rearranged genome, associated with whole genome doubling, which is identified in more than half …
View article: Endometrial Stromal Sarcoma: An Update
Endometrial Stromal Sarcoma: An Update Open
Endometrial stromal sarcoma (ESS) is a rare malignant tumor of uterine mesenchyme, accounting for 15–20% of uterine sarcomas. It is classified into low-grade (LG-ESS) and high-grade (HG-ESS) subtypes, each defined by distinct histopatholog…
View article: Peritonectomy procedures for peritoneal surface malignancies: PSOGI-ESGO-ISSPP Lyon consensus
Peritonectomy procedures for peritoneal surface malignancies: PSOGI-ESGO-ISSPP Lyon consensus Open
Background The nomenclature and execution of peritonectomy procedures for peritoneal surface malignancies significantly vary between surgeons and centres. The aim of this consensus was to reach uniform nomenclature for peritonectomy proced…
Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer (CHIPOR): A Randomized, Open-Label, Phase 3 Trial Open
(Abstracted from Lancet Oncol 2024;25(12):1551–1562) The leading cause of death due to gynecological cancer is from ovarian cancer. Long-term survival is associated with complete surgical resection and a prolonged platinum-free interval.
View article: Management of Recurrence in Ovarian Cancer—The Role of Surgery and HIPEC with Relevance to BRCA Testing in a PARPi Landscape
Management of Recurrence in Ovarian Cancer—The Role of Surgery and HIPEC with Relevance to BRCA Testing in a PARPi Landscape Open
Background: The surgical and medical management of recurrent ovarian cancer is complex and requires a personalized approach based on several factors, including the timing of recurrence, the patient’s performance status, previous treatment …
View article: Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial
Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial Open
Early decrease of ctDNA ratio can provide prognostic information early in the management of patients, allowing a more accurate information to patients and an early preparation for CRS (prehabilitation).
View article: Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy
Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy Open
PURPOSE Simple hysterectomy and pelvic node assessment (SHAPE) is a phase III randomized trial (ClinicalTrials.gov identifier: NCT01658930 ) reporting noninferiority of simple compared with radical hysterectomy for oncologic outcomes in lo…
View article: Supplementary Figure S4 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Figure S4 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Feature plots of relevant immune populations in pre- and post-NACT clusters
View article: Supplementary Figure S2 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Figure S2 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Change in GrzB expression min paired samples post-NACT
View article: Supplementary Table S4 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Table S4 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Change in iTME (macrophages/APCS) with NACT in paired samples
View article: Supplementary Table S6 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Table S6 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Correlation among the different immune coregulators in pre- and post-NACT tumors
View article: Supplementary Table S4 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Table S4 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Change in iTME (macrophages/APCS) with NACT in paired samples
View article: Supplementary Table S5 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Table S5 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Change in immune coregulators expression in intraepithelial (ie+) and stromal compartment (s+) in pre- and post-NACT tumors
View article: Supplementary Table S1 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Table S1 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Primary antibodies used in the multiplex panels for the detection of the different immune populations
View article: Data from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Data from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Purpose:This study investigates changes in CD8+ cells, CD8+/Foxp3 ratio, HLA I expression, and immune coregulator density at diagnosis and upon neoadjuvant chemotherapy (NACT), correlating changes with clinical outcomes.Experimental Design…
View article: Data from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Data from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Purpose:This study investigates changes in CD8+ cells, CD8+/Foxp3 ratio, HLA I expression, and immune coregulator density at diagnosis and upon neoadjuvant chemotherapy (NACT), correlating changes with clinical outcomes.Experimental Design…
View article: Supplementary Table S3 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Table S3 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Patients and diseases baseline characteristics in the CHIVA neoadjuvant trial
View article: Supplementary Figure S2 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Figure S2 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Change in GrzB expression min paired samples post-NACT
View article: Supplementary Figure S3 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Figure S3 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Change in ieCD8+ and sCD8+ populations in paired samples with NACT
View article: Supplementary Table S2 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Table S2 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Primary antibodies used for IHC monomarker detection
View article: Supplementary Figure S3 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Supplementary Figure S3 from Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy Open
Change in ieCD8+ and sCD8+ populations in paired samples with NACT